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Background
Cancers of the hepatobiliary tract (liver, bile duct and
gall bladder) are characterized by relatively infrequent
occurrence, aggressive growth, and recurrences after
treatment. Hepatocellular carcinoma (HCC) is of special
c o n c e r ni nt h ec o n t e x to fH I V / A I D Sd u et os u b s t a n t i a l
associated morbidity and mortality. The overall burden
of liver cancer may increase in people with AIDS as the
combined effects of alcohol use, coinfection with hepati-
tis C virus (HCV) and hepatitis B virus (HBV), and
other risk factors manifest as chronic liver disease.
Methods
Registry linkage data from the U.S. HIV/AIDS Cancer
Match Study were used to estimate standardized inci-
dence ratios (SIRs) to compare the risk of hepatobiliary
cancers in people with HIV/AIDS to the general popula-
tion. We also estimated rate ratios (RRs) of HCC by HIV
risk group, calendar period and AIDS status. HIV risk
groups were categorized by HCV prevalence [high preva-
lence: hemophiliacs, injection drug users (IDUs), and
IDU-men who had sex with men (MSM); and low preva-
lence: heterosexuals, non-IDU MSM, and others].
Results
Compared to the general population, people with AIDS
had higher risk for HCC (366 observed cases, SIR: 3.85;
95%CI: 3.47-4.27). SIRs were also elevated for other liver
and intrahepatic bile duct tumors (27 cases, SIR: 3.26;
95%CI: 2.15-4.75), but not for cholangiocarcinomas (22
cases, SIR: 1.36; 95%CI: 0.85-2.05) or gallbladder tumors
(11 cases, SIR: 1.39; 95%CI: 0.70-2.49). Adjusted for sex
and age, people with high HCV prevalence were at
higher risk for HCC than people with lower HCV preva-
lence (RR: 2.12; 95%CI: 1.72-2.60). SIRs were elevated
for all HIV risk groups, with the highest SIRs among
hemophiliacs (40.4), IDUs (5.59), and IDU-MSM (4.39).
Steadily increasing risk among persons with AIDS was
observed across calendar time, including during the
HAART era (Figure 1)In an analysis limited to registry
areas with data on HIV-infected people without AIDS),
persons with AIDS had higher HCC risk than persons
with HIV-only (RR: 2.59; 95% CI: 1.71-3.91).
Conclusion
This study reinforces the primary role of HCV coinfec-
tion in HCC pathogenesis in persons with AIDS in the
United States. HCC risk is higher in people with AIDS
than people with HIV infection without AIDS, consis-
tent with a contribution from prolonged immunosup-
pression. Rising HCC incidence in the era of HAART
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negative impact of HIV on HCV-related cirrhosis,
and that access to appropriate anti-HCV therapies in
HIV-infected individuals is critical for prevention of
progression to HCC.
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